The European Commission has granted marketing authorization to Yuflyma, a biosimilar to Humira (adalimumab), making it available treat chronic inflammatory diseases.
Investegate announcements from Galapagos NV, Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress
Celebrating EULAR's 75th anniversary with focus on a new era of rheumatoid arthritis care Mechelen, Belgium; 25 May 2022, 22.01 CET; Galapagos NV (Euronext & Nasdaq: GLPG) will
Research to be presented on Orencia, deucravacitinib and pipeline assets highlights breadth of data and focus on transforming treatment paradigms for people living with rheumatic diseases Bristol Myers Squibb today announced data from 29 company-sponsored presentations across Orencia, deucravacitinib and pipeline assets will be presented at the American College of Rheumatology Convergence 2021, taking place .